tiprankstipranks
Advertisement
Advertisement

IBIO Stock Latest News

iBio appoints Molly Carr as chief medical officer
The FlyiBio appoints Molly Carr as chief medical officer
15d ago
LLY
IBIO
iBio Appoints Molly Carr as Chief Medical Officer
PremiumCompany Announcements
iBio Appoints Molly Carr as Chief Medical Officer
15d ago
8K
IBIO
iBio Updates Governance Deadlines for 2026 Annual Meeting
PremiumCompany Announcements
iBio Updates Governance Deadlines for 2026 Annual Meeting
1M ago
8K
IBIO
Buy Rating Reiterated on iBio as IBIO-610 Data Underscore Differentiated Efficacy; $5 Price Target Maintained
PremiumRatings
Buy Rating Reiterated on iBio as IBIO-610 Data Underscore Differentiated Efficacy; $5 Price Target Maintained
2M ago
IBIO
iBio Highlights Promising New Preclinical Obesity Antibody Data
PremiumCompany Announcements
iBio Highlights Promising New Preclinical Obesity Antibody Data
2M ago
8K
IBIO
iBio announces new preclinical data from IBIO-610 study
PremiumThe FlyiBio announces new preclinical data from IBIO-610 study
2M ago
IBIO
iBio initiated with an Outperform at Raymond James
Premium
The Fly
iBio initiated with an Outperform at Raymond James
2M ago
IBIO
iBio doses first participant in IBIO-600 trial
Premium
The Fly
iBio doses first participant in IBIO-600 trial
3M ago
IBIO
IBIO-600 First-in-Human Obesity Trial Puts iBio on Investors’ Radar
PremiumCompany Announcements
IBIO-600 First-in-Human Obesity Trial Puts iBio on Investors’ Radar
3M ago
IBIO
iBio reports Q3 EPS (7c), consensus (6c)
PremiumThe Fly
iBio reports Q3 EPS (7c), consensus (6c)
3M ago
IBIO
iBio Strengthens Board with Appointment of Dr. Stoner
PremiumCompany Announcements
iBio Strengthens Board with Appointment of Dr. Stoner
3M ago
8K
IBIO
Validating iBio’s Antibody Platform: Buy Rating Driven by IBIO-600’s Differentiated Obesity Profile and Long-Acting Myostatin Inhibition
PremiumRatings
Validating iBio’s Antibody Platform: Buy Rating Driven by IBIO-600’s Differentiated Obesity Profile and Long-Acting Myostatin Inhibition
4M ago
IBIO
iBio Advances to Clinical Stage With IBIO-600 Trial
PremiumCompany AnnouncementsiBio Advances to Clinical Stage With IBIO-600 Trial
4M ago
8K
IBIO
iBio receives regulatory clearance to initiate IBIO-600 trial in Australia
Premium
The Fly
iBio receives regulatory clearance to initiate IBIO-600 trial in Australia
4M ago
IBIO
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
5M ago
ACOG
IBIO
Insiders Rock Asana, Ibio, Redwire, AFLAC, Sibanye Stillwater
PremiumWeekend Updates
Insiders Rock Asana, Ibio, Redwire, AFLAC, Sibanye Stillwater
5M ago
AFL
RDW
iBio (IBIO-610): Validated Activin E Mechanism, Strategic Trial Positioning, and Attractive Risk-Reward Support a Buy Rating
PremiumRatings
iBio (IBIO-610): Validated Activin E Mechanism, Strategic Trial Positioning, and Attractive Risk-Reward Support a Buy Rating
5M ago
IBIO
Buy Rating on iBio Driven by Differentiated Activin-Targeting Antibody and Large PH-HFpEF Market Opportunity
PremiumRatings
Buy Rating on iBio Driven by Differentiated Activin-Targeting Antibody and Large PH-HFpEF Market Opportunity
5M ago
IBIO
iBio to provide update on cardiopulmonary program
PremiumThe Fly
iBio to provide update on cardiopulmonary program
5M ago
IBIO
Buy Rating on iBio Driven by Promising IBIO-610 Obesity Data and Favorable Risk-Reward Profile
PremiumRatingsBuy Rating on iBio Driven by Promising IBIO-610 Obesity Data and Favorable Risk-Reward Profile
5M ago
IBIO
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential
Premium
Company Announcements
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential
5M ago
8K
IBIO
iBio announces new preclinical data from study evaluating IBIO-610
Premium
The Fly
iBio announces new preclinical data from study evaluating IBIO-610
5M ago
IBIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >